Skip to main content
Premium Trial:

Request an Annual Quote

Quintiles Acquires Targeted Molecular Diagnostics

NEW YORK (GenomeWeb News) – Quintiles Transnational today said that it has acquired Targeted Molecular Diagnostics, a privately held lab focused on oncology testing using biomarker expression analysis technologies, for an undisclosed sum.
 
Quintiles said that the Westmont, Ill.-based lab will provide it with “strong capabilities in tissue-based testing.” It also said that TMD’s biomarker technology will help Quintiles’ customers gain a greater understanding of how their drugs work and which populations are most likely to benefit from their therapies.
 
“With the addition of TMD’s expertise, we can help customers develop novel, targeted cancer therapies and get them to market much faster by employing biomarkers in the development process,” King Jolly, senior vice president of drug development partnerships for NovaQuest, the managed partnership group of Quintiles.
 
TMD currently supports clinical trials being conducted in more than 40 countries, and it offers more than 100 biomarker assays, said Quintiles.

The Scan

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.